Trials / Completed
CompletedNCT03015909
Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.
A Multi-center, Open, Single-arm, Switch-over, Prospective, Phase IV Study to Assess the Ease of Use, Preference, and Safety After 8 Weeks Subcutaneous Administration of EutropinPen Inj. in Patients Pretreated With Recombinant Human Growth Hormone by Reusable Device
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- LG Life Sciences · Industry
- Sex
- All
- Age
- 4 Years – 15 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.
Conditions
- Short Stature, Idiopathic
- Infant, Small for Gestational Age
- Growth Hormone Deficiency
- Chronic Renal Failure
- Turner Syndrome
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Somatropin |
Timeline
- Start date
- 2016-08-11
- Primary completion
- 2017-12-21
- Completion
- 2017-12-21
- First posted
- 2017-01-10
- Last updated
- 2019-01-03
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03015909. Inclusion in this directory is not an endorsement.